Co-Diagnostics, Inc.
CODX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.07 | 0.01 | -0.18 |
| FCF Yield | -45.88% | -93.66% | -89.06% | -33.50% |
| EV / EBITDA | -0.45 | 0.02 | -1.37 | -2.08 |
| Quality | ||||
| ROIC | -14.01% | -18.52% | -16.90% | -20.66% |
| Gross Margin | 81.92% | 80.29% | 57.06% | -70.81% |
| Cash Conversion Ratio | 1.00 | 1.07 | 1.16 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -52.23% | -48.38% | -33.92% | -52.36% |
| Free Cash Flow Growth | 31.18% | 1.68% | -6.42% | -12.16% |
| Safety | ||||
| Net Debt / EBITDA | 1.47 | 1.21 | -0.00 | 0.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.03 | 0.02 | 0.24 |
| Cash Conversion Cycle | -1,226.94 | -1,426.81 | -6,547.88 | -703.96 |